Zoltán Kaló

Zoltán Kaló publication distribution in Economics and Finance in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Economics and Finance in 2026. The highlighted bar marks where Zoltán Kaló sits on this spectrum.

Zoltán Kaló D-index placement in Economics and Finance in 2026

The chart shows the D-index (discipline H-index) distribution of Economics and Finance scientists ranked by Research.com in 2026. The highlighted bar marks where Zoltán Kaló sits on this spectrum.

Best Publications

• Multiple Criteria Decision Analysis for Health Care Decision Making—An Introduction: Report 1 of the ISPOR MCDA Emerging Good Practices Task Force

  Praveen Thokala;Nancy Devlin;Kevin Marsh;Rob Baltussen

  787
  Citations

• Multiple Criteria Decision Analysis for Health Care Decision Making—Emerging Good Practices: Report 2 of the ISPOR MCDA Emerging Good Practices Task Force

  Kevin Marsh;Maarten IJzerman;Praveen Thokala;Rob Baltussen

  525
  Citations

• Comparison of weighting methods used in multicriteria decision analysis frameworks in healthcare with focus on low- and middle-income countries.

  Bertalan Németh;Anett Molnár;Sándor Bozóki;Sándor Bozóki;Kalman Wijaya

  134
  Citations

• Cost-effectiveness of organ donation: evaluating investment into donor action and other donor initiatives.

  James F. Whiting;Bryce Kiberd;Zoltan Kalo;Paul Keown

  131
  Citations

• Challenges in Research and Health Technology Assessment of Rare Disease Technologies: Report of the ISPOR Rare Disease Special Interest Group.

  Sandra Nestler-Parr;Daria Korchagina;Mondher Toumi;Chris L. Pashos

  108
  Citations

• The cost effectiveness of Apligraf® treatment of diabetic foot ulcers

  W. Ken Redekop;Joseph McDonnell;Paul Verboom;Kornelia Lovas

  102
  Citations

• Diabetic foot ulcers and amputations: estimates of health utility for use in cost-effectiveness analyses of new treatments.

  W K Redekop;E A Stolk;E Kok;K Lovas

  100
  Citations

• HTA Implementation Roadmap in Central and Eastern European Countries.

  Zoltán Kaló;Adrian Gheorghe;Mirjana Huic;Marcell Csanádi

  97
  Citations

• Principles of pharmacoeconomics and their impact on strategic imperatives of pharmaceutical research and development

  József Bodrogi;Zoltán Kaló

  81
  Citations

• Resource use and treatment costs after kidney transplantation: impact of demographic factors, comorbidities, and complications.

  Ernst-Günther Hagenmeyer;Bertram Häussler;Elke Hempel;Gerrit Grannas

  77
  Citations

• Capacity Building for HTA Implementation in Middle-Income Countries: The Case of Hungary

  Zoltán Kaló;József Bodrogi;Imre Boncz;Imre Boncz;Csaba Dózsa

  70
  Citations

• Is there a reason for concern or is it just hype? - A systematic literature review of the clinical consequences of switching from originator biologics to biosimilars.

  András Inotai;Christiaan P J Prins;Marcell Csanádi;Dinko Vitezic

  67
  Citations

• Implementation of Health Technology Assessment in the Middle East and North Africa: Comparison Between the Current and Preferred Status.

  Ahmad Fasseeh;Rita Karam;Mouna Jameleddine;Mohsen George

  65
  Citations

• The European challenges of funding orphan medicinal products

  Márta Szegedi;Tamás Zelei;Francis Arickx;Anna Bucsics

  63
  Citations

• Economic evaluation of kidney transplantation versus hemodialysis in patients with end-stage renal disease in Hungary

  Zoltán Kaló;Jeno Járay;Júlia Nagy

  60
  Citations

• Cost-effectiveness analysis of intensity-modulated radiation therapy with normal and hypofractionated schemes for the treatment of localised prostate cancer.

  A.T. Zemplényi;Z. Kaló;G. Kovács;R. Farkas

  58
  Citations

• Systematic review on the evaluation criteria of orphan medicines in Central and Eastern European countries

  Tamás Zelei;Mária J. Molnár;Márta Szegedi;Zoltán Kaló

  58
  Citations

• Recommendations for Reporting Pharmacoeconomic Evaluations in Egypt

  Gihan H. Elsisi;Zoltán Kaló;Randa Eldessouki;Mahmoud D. Elmahdawy

  57
  Citations

• Healthcare financing in Egypt: a systematic literature review.

  Unknown

  53
  Citations

• Policy objective of generic medicines from the investment perspective: The case of clopidogrel.

  Péter Elek;András Harsányi;Tamás Zelei;Kata Csetneki

  10
  Citations